The spread of cancer to the brain is called metastasis and indicates an advanced stage of the disease. Life expectancy in this situation varies depending on the type of disease, the patient's general health, the number and size of the metastases, the treatment methods used, and the biological characteristics of the cancer. Here is a detailed explanation:
1. Life Expectancy by Cancer Type
- Lung Cancer: Brain metastases are most commonly seen in lung cancer. Without treatment, survival generally ranges from a few weeks to a few months. With treatment (for example radiotherapy, surgery, or targeted therapies), this can extend up to 6-12 months.
- Breast Cancer: Survival may be longer when brain metastases occur in breast cancer types that respond to hormonal or targeted therapy. With treatment, average survival can reach 12-18 months.
- Melanoma: When melanoma metastasizes to the brain, it follows an aggressive course. Survival in untreated patients is generally a few months, but it can be prolonged with immunotherapy and radiosurgery.
- Colon Cancer and Other Types: These metastasize to the brain less frequently. Average survival is generally limited to a few months.
2. Number and Size of Metastases
- Single Metastasis: When a single brain metastasis is removed with surgery and radiotherapy, survival may be prolonged. In patients who are candidates for surgery, a survival of 1-2 years or more may be possible.
- Multiple Metastases: When more than one metastasis is present, treatment becomes more difficult and survival is generally shorter.
3. Effect by Treatment Type
- Steroids: Steroids, used to reduce swelling (edema) in the brain, can provide short-term relief.
- Radiotherapy: Whole-brain radiotherapy (WBRT) can extend survival by a few months, but cognitive side effects may occur.
- Stereotactic Radiosurgery (SRS): It is highly effective for small metastases and has fewer side effects.
- Surgery: In patients with a single metastasis who are suitable candidates, surgery can significantly increase survival.
- Targeted Therapies: For example, drugs used in lung cancer patients with an EGFR mutation or ALK fusion can be effective against metastases.
- Immunotherapy: It plays an important role in controlling brain metastases in some cancer types such as melanoma.
4. The Patient's General Health
- Performance Status: Patients with a good Karnofsky Performance Scale (KPS) or ECOG status can generally live longer.
- Age and Other Diseases: In elderly patients and those in poor general health, the response to treatment is more limited.
5. Prognosis (Expected Survival)
- Without Treatment: Average survival is 1-2 months.
- With Radiotherapy and Steroids: 3-6 months.
- With Radiosurgery or Surgery: 6-18 months.
- With Targeted Therapies or Immunotherapy: In patients with a suitable genetic mutation, this can be several years.
6. Improving Quality of Life
- Pain and Edema Control: Achieved with steroids and pain relievers.
- Psychosocial Support: Psychological support for the patient and family during this process is important.
- Palliative Care: Approaches aimed at improving the patient's quality of life (for example, nutrition, mobility, and symptom management).